Advertisement

Topics

Latest "Copernicus Therapeutics" News Stories

14:08 EST 15th December 2018 | BioPortfolio

Here are the most relevant search results for "Copernicus Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Copernicus Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Copernicus Therapeutics for you to read. Along with our medical data and news we also list Copernicus Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Copernicus Therapeutics Companies for you to search.

Showing "Copernicus Therapeutics" News Articles 1–25 of 8,100+

Extremely Relevant

M&As this week: WIRB-Copernicus, AbCellera Biologics, Apricus Biosciences

WIRB-Copernicus Group has completed the acquisition of KMR Group and Metrics Champion Consortium (MCC) for an undisclosed sum. The acquired...Read More... The post M&As this week: WIRB-Copernicus, AbCellera Biologics, Apricus Biosciences appeared first on Drug Development Technology.


Relevant

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS

Copernicus Plans Liberal Licensing for its Advanced DNA Delivery Technology

Imagine, for a moment, that every drug on the market suddenly didn’t work because of the lack of an adequate delivery system. That’s precisely the situation gene therapy companies find themselves in today...


Copernicus Award 2018: Outstanding German-Polish cooperation in cardiology

(Deutsche Forschungsgemeinschaft) Cardiologists from Berlin and Wrocaw to receive the award from the DFG and the Foundation for Polish Science / Award ceremony to take place on October 25 in Berlin.

Harnessing Earth-observation data for practical healthcare applications

The EU-funded AURORA project will develop technologies to turn data from the Sentinel-4 and Sentinel-5 missions – due to be launched as part of the European Space Agency’s Copernicus programme – into practical, actionable information that will help protect the health of European citizens.

M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...Read More... The post M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin appeared first on Drug Development Technology.

Roche’s Genentech agrees to buy Jecure Therapeutics

Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CEO The post Roche’s Genentech agrees to buy Jecure Therapeutics appeared first on Pharmaceutical Business review.

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. Specific The post HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics appeared first on Pharma Business review.

Small-Cap Snapshot: Galectin Therapeutics flies after receiving a patent for treating pulmonary fibrosis

Aquinox Pharmaceuticals, Summit Therapeutics and Global Blood Therapeutics are also making news

Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics

Pliant Therapeutics has raised $62m through a series B financing round from Cowen Healthcare Investments. The funding round also included participation...Read More... The post Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics appeared first on Drug Development Technology.

iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

Probably Relevant

Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng). Existing investor Lilly Asian Ventures (LAV)...Read More... The post Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics appeared first on Drug Development Technology.

SCISYS Group (158355634SSY) - Move protects the group’s space business

Edison Investment Research - Technology - SCISYS Group: After obtaining shareholder approval and subsequent court sanctioning, SCISYS has re-domiciled in the Republic of Ireland. The change will ensure that its German-based space business can continue to work on EU-funded space programmes, such as EGNOS, Galileo and Copernicus. SCISYS decided to finalise the move in Q4 as it is too risky to wait f...

Dermatology start-up Hoth Therapeutics files for IPO

Hoth Therapeutics Inc. (technology that creates a topical agent from existing therapeutics to treat skin diseases) filed for ...

Nabriva Acquires Zavante Therapeutics and its Late-Stage Antibiotic

Shares of Nabriva Therapeutics are rising this morning after the company announced it acquired privately-held Zavante Therapeutics.

HiFiBio acquires H-Immune Therapeutics

HiFiBio Therapeutics acquired French biotech H-Immune Therapeutics, a privately held firm developing immuno-oncology therapie...

AdoRx raises $10m funding to discover new cancer therapeutics

UK-based AdoRx Therapeutics, which is focused on discovering new cancer therapeutics, has secured an initial $10m investment round financed by Epidarex Capital and CRT Pioneer Fund (CPF).

SMi Group announces the 10th Annual RNA Therapeutics Conference

20 - 21 February 2019, London, UK. Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

Appointments: New CEO For Silence Therapeutics, Medical Heads Join Merck, Breath Therapeutics, Immusoft

David Solomon’s entrance as Silence Therapeutics’ new CEO leads this week’s new hires. While Ireland-based Malin shakes up its board...    

Carisma Therapeutics to expand its technology platform towards clinical development

Carisma Therapeutics Inc., formerly CARMA Therapeutics, a privately─held biotechnology company focused on the development of macrophage─based immunotherapeutics, announced the close of a $53 million Series A

e-therapeutics, Novo Nordisk enter into research collaboration deal

Under the agreement, the two companies will use e-therapeutics’ network-driven drug discovery platform for the identification of new therapeutics approaches to treat Type 2 diabetes, which currently accounts The post e-therapeutics, Novo Nordisk enter into research collaboration deal appeared first on Pharmaceutical Business review.

Summit Therapeutics plc: Summit Therapeutics to Present at the Canaccord Genuity Growth Conference

Summit Therapeutics plc('Summit', or the 'Company')Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceOxford, UK, and Cambridge, MA, US, 6 August 2018 - Summit Therapeutics p...

PTC Therapeutics to commercialise Akcea’s two rare disease drugs

Ionis Pharmaceuticals affiliate Akcea Therapeutics has signed an agreement with biopharmaceutical company PTC Therapeutics for the commercialisation of its rare...Read More... The post PTC Therapeutics to commercialise Akcea’s two rare disease drugs appeared first on Pharmaceutical Technology.

From Parkinson’s to asthma: opportunities for microbiome-based therapeutics

On September 5, speakers at the Microbiome Therapeutics US conference shed light on the future of microbiome therapeutics, which is...Read More... The post From Parkinson’s to asthma: opportunities for microbiome-based therapeutics appeared first on Pharmaceutical Technology.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks